Updated Jul 23, 2026
/Utah Medical Products revenue falls 14.3% in Q2 2026 as two former top customers book zero in sales/SL Green Realty reports 30.6 million-square-foot Manhattan portfolio as of June 30/Nasdaq orders Nuvve Holding Corp. delisted, trading to halt July 24/Alphabet and Tesla shares fall as AI outlays weigh on quarterly growth/UniCredit CEO Orcel says Commerzbank acquisition could happen in fourth quarter/Jefferies steers summer clients toward quality stocks left behind by AI trade/Utah Medical Products revenue falls 14.3% in Q2 2026 as two former top customers book zero in sales/SL Green Realty reports 30.6 million-square-foot Manhattan portfolio as of June 30/Nasdaq orders Nuvve Holding Corp. delisted, trading to halt July 24/Alphabet and Tesla shares fall as AI outlays weigh on quarterly growth/UniCredit CEO Orcel says Commerzbank acquisition could happen in fourth quarter/Jefferies steers summer clients toward quality stocks left behind by AI trade
A darkened newsroom before dawn, monitors glowing and a single red LIVE light over the anchor desk
Markets desk · July 23, 2026

Utah Medical Products revenue falls 14.3% in Q2 2026 as two former top customers book zero in sales

Second-quarter revenues for Utah Medical Products, Inc. (Nasdaq: UTMD) fell 14.3% to $8.529 million from $9.953 million a year earlier, the company disclosed Wednesday, with zero sales from two previously top accounts responsible for 75% of the shortfall. The Salt Lake City medic

Latest from the wire

See all bulletins →

Top of the hour

Updated July 23, 2026

The Wire — newest first

Every bulletin dated and ordered by recency. Older stories fade down the board as fresher ones break.

See all bulletins
The alert, before the trend

Don't refresh the feed. Let the feed find you.

Subscribe and we'll send the bulletin the instant our desk confirms it — verified, timestamped, and straight to your inbox.

Subscribe by email